In last trading session, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) saw 0.39 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $0.54 trading at -$0.05 or -9.10% at ring of the bell on the day assigns it a market valuation of $49.31M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.4 million shares which gives us an average trading volume of 416.25K if we extend that period to 3-months.

For Verrica Pharmaceuticals Inc (VRCA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information

Upright in the red during last session for losing -9.10%, in the last five days VRCA remained trading in the red while hitting it’s week-highest on Tuesday, 03/11/25 when the stock touched $0.54 price level, adding 20.01% to its value on the day. Verrica Pharmaceuticals Inc’s shares saw a change of -23.24% in year-to-date performance and have moved -11.63% in past 5-day. Verrica Pharmaceuticals Inc (NASDAQ:VRCA) showed a performance of -17.34% in past 30-days. Number of shares sold short was 2.03 million shares which calculate 8.36 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 95.5% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -1751.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1751.85% for stock’s current value.

Verrica Pharmaceuticals Inc (VRCA) estimates and forecasts

This year revenue growth is estimated to rise 122.74% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.6M for the same. And 5 analysts are in estimates of company making revenue of 3.67M in the next quarter. Company posted 3.83M and 5.18M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.97% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 70.00% while estimates for its earnings growth in next 5 years are of 60.68%.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders

Insiders are in possession of 43.30% of company’s total shares while institution are holding 32.63 percent of that, with stock having share float percentage of 57.56%. Investors also watch the number of corporate investors in a company very closely, which is 32.63% institutions for Verrica Pharmaceuticals Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at VRCA for having 7.1 million shares of worth $51.75 million. And as of 2024-06-30, it was holding 15.2663 of the company’s outstanding shares.

The second largest institutional holder is AVORO CAPITAL ADVISORS LLC, which was holding about 4.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6017 of outstanding shares, having a total worth of $29.16 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.3 shares of worth $0.7 million or 1.41% of the total outstanding shares. The later fund manager was in possession of 567.67 shares on Dec 31, 2024 , making its stake of worth around $0.31 million in the company or a holder of 0.62% of company’s stock.